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Response to mTOR inhibition: activity of eIF4E
predicts sensitivity in cell lines and acquired
changes in eIF4E regulation in breast cancer
Sampoorna Satheesha1, Victoria J Cookson1, Louise J Coleman1, Nicola Ingram1, Brijesh Madhok1,
Andrew M Hanby2, Charlotte AB Suleman2, Vicky S Sabine3, E Jane Macaskill3, John MS Bartlett3,4,
J Michael Dixon4, Jim N McElwaine5, Thomas A Hughes1*
Abstract
Background: Inhibitors of the kinase mTOR, such as rapamycin and everolimus, have been used as cancer
therapeutics with limited success since some tumours are resistant. Efforts to establish predictive markers to allow
selection of patients with tumours likely to respond have centred on determining phosphorylation states of mTOR
or its targets 4E-BP1 and S6K in cancer cells. In an alternative approach we estimated eIF4E activity, a key effector
of mTOR function, and tested the hypothesis that eIF4E activity predicts sensitivity to mTOR inhibition in cell lines
and in breast tumours.
Results: We found a greater than three fold difference in sensitivity of representative colon, lung and breast cell
lines to rapamycin. Using an assay to quantify influences of eIF4E on the translational efficiency specified by
structured 5’UTRs, we showed that this estimate of eIF4E activity was a significant predictor of rapamycin
sensitivity, with higher eIF4E activities indicative of enhanced sensitivity. Surprisingly, non-transformed cell lines
were not less sensitive to rapamycin and did not have lower eIF4E activities than cancer lines, suggesting the
mTOR/4E-BP1/eIF4E axis is deregulated in these non-transformed cells. In the context of clinical breast cancers, we
estimated eIF4E activity by analysing expression of eIF4E and its functional regulators within tumour cells and
combining these scores to reflect inhibitory and activating influences on eIF4E. Estimates of eIF4E activity in cancer
biopsies taken at diagnosis did not predict sensitivity to 11-14 days of pre-operative everolimus treatment, as
assessed by change in tumour cell proliferation from diagnosis to surgical excision. However, higher pre-treatment
eIF4E activity was significantly associated with dramatic post-treatment changes in expression of eIF4E and
4E-binding proteins, suggesting that eIF4E is further deregulated in these tumours in response to mTOR inhibition.
Conclusions: Estimates of eIF4E activity predict sensitivity to mTOR inhibition in cell lines but breast tumours with
high estimated eIF4E activity gain changes in eIF4E regulation in order to enhance resistance.
Background
Rapamycin is an immunosuppressant drug prescribed for
prophylaxis of organ rejection following renal transplant
[1]. Recently it, and derivatives such as everolimus, have
been tested as cancer therapeutics with some success
[2-5]. The drugs inhibit the serine/threonine-specific pro-
tein kinase mTOR (mammalian Target Of Rapamycin) by
forming a complex with another protein, FKBP12 (FK
506-binding protein of 12 kDa), that then associates with
mTOR. This association allosterically inhibits mTOR’s
ability to assemble the functionally active complex
mTORC1 (mTOR complex 1) [6,7]. In addition, at high
doses the drugs can bind directly to mTOR inhibiting its
function [8]. mTORC1 activity is up-regulated in many
cancers as a result of loss of function of tumour suppres-
sor genes such as p53 or LKB1, up-regulation of AKT, or
mitogenic signalling [9-11]. Pathways downstream of
mTORC1 that contribute to carcinogenesis have also
been defined. The main mTORC1 targets are the eIF4E-
binding proteins (4E-BP1, 2 and 3) and the S6 protein
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kinases (S6K1 and 2) [12,13]. Hypophosphorylated
4E-BPs bind to and inhibit the translation factor eIF4E,
while these interactions are inhibited by mTORC1-
dependent 4E-BP phosphorylation, releasing active eIF4E
[14]. S6K activity is stimulated by phosphorylation by
mTORC1. The result of increased activity of both eIF4E
and S6K is changes in translation. Increased eIF4E activ-
ity enhances cap-dependent translation of mRNAs with a
high degree of secondary structure within their
5’ untranslated regions (UTRs) [15,16], a subset of tran-
scripts greatly enriched for cancer-related messages [17].
In addition, nuclear export of some cancer-related tran-
scripts is stimulated by highly active eIF4E [18,19].
Increased S6K activity leads to up-regulation of overall
translational capacity, as a result of increased ribosome
biogenesis, and may also contribute to enhanced transla-
tion of transcripts with structured 5’UTRs via up-
regulation of the activity of the translation factor eIF4A
[20]. Therefore, increased mTORC1 activity in cancer
enhances expression of key oncogenes and increases cel-
lular growth potential. Reversing these effects, and
thereby reducing cell growth or inducing apoptosis, is
thought to be the basis of the therapeutic action of
mTOR inhibitors in cancer.
However, mTOR inhibitors have proved less success-
ful in cancer clinical trials than might be hoped from
the importance of the molecular pathways involved [2].
This relates partly to some toxicity in non-target tissues
[21,22], but also to intrinsic or acquired resistance in
many individual cancers. Consequently, there is a need
for predictive biomarkers to allow selection of patients
with cancers most likely to respond to such agents.
A number of potential biomarkers have been discussed
in the literature, focusing on expression levels or phos-
phorylation states of mTOR itself [23], or the immediate
targets of mTORC1, 4E-BP1 [24,25] and S6K1 [26,27].
Here, we take a different approach and estimate the
activity of eIF4E, one of the key effectors of mTORC1
function, and investigate whether this reflects response
to mTOR inhibition in both tissue culture and in clini-
cal breast cancers.
Methods
Cell culture, transfection, proliferation assays
Cell lines were obtained from American Tissue Culture
Collection or European Collection of Animal Cell Cul-
tures and were maintained at 37°C in humidified air/5%
CO2. Bi-monthly mycoplasma checks (MycoAlert assay;
Lonza, Basel, Switzerland) were consistently negative. Cell-
specific culture/transfection conditions are described in
Additional file 1, Table S1. Plasmids pTH-GFPa (control
GFP reporter) [28], GFP+60 (structured GFP reporter)
[29] and pcDNA3HA-eIF4E [30] have been described pre-
viously. For proliferation assays, cells were plated into 96-
well, flat-bottomed plates at 5 × 103-2 × 104 cells/well
(depending on cell line growth characteristic to ensure
continued log phase growth; this was assessed by examina-
tion of growth of DMSO-treated cells over 48 h). Five
replicate wells were treated with DMSO (control) or InSo-
lution™ Rapamycin (Calbiochem, Darmstadt, Germany)
for 24 (data not shown) or 48 h. Metabolically active cells
were quantified by assessing conversion of 3-(4,5-
Dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bro-
mide (Sigma-Aldrich, Dorset, UK) to formazan. Formazan
was dissolved in propan-1-ol and quantified as absorbance
at 570 nm (Opsys, Dynex, Sussex, UK).
Western blotting
Proteins were extracted in RIPA (50 mM Tris HCl pH
7.4, 150 mM NaCl, NP40 1%, Complete inhibitors
[Roche, Basel, Switzerland]) and were quantified in tri-
plicate with the RCDC protein assay (BioRad, Hercules,
USA). 20 μg of protein was loaded into wells of 12%
NuPAGE bis-tris gels running in MOPS NuPAGE buf-
fer (Invitrogen, Paisley, UK). Proteins were transferred
to PDVF membrane (Millipore, Billerica, USA) in
NuPAGE transfer buffer (Invitrogen, Paisley, UK).
Membranes were blocked and incubated with antibo-
dies in 5% dried milk in TBS-T (Tris-buffered saline-
0.1% Tween 20) and were washed in TBS-T. Primary
antibodies: rabbit monoclonal anti-phosphoThr37/46
4E-BP1, 1:500, and rabbit polyclonal anti-4E-BP1,
1:500 (#2855 and #9452, Cell Signalling Technology,
Beverly, USA); mouse monoclonal anti-eIF4E, 1:500
(sc9976, Santa Cruz, USA). We have previously vali-
dated specificities of these antibodies, including the
phospho-specificity of the anti-phospho clone [31],
although we cannot exclude that the anti-phospho-4E-
BP1 may cross-react with phospho-4E-BP2 or 3. Sec-
ondary antibodies: anti-mouse/rabbit HRP conjugates,
1:1000 (DAKO, Glostrup, Denmark). Proteins were
detected using Supersignal West Femto (Thermo
Fisher, Waltham, USA) and Chemidoc XRS (BioRad,
Hercules, USA), and analysed using ImageJ 1.42q
(NIH, http://rsb.info.nih.gov/ij).
Translational efficiency assay
We have previously reported the protocol in consider-
able detail [32,33]. In brief, relative GFP protein and
mRNA levels were used to calculate amounts of GFP
protein produced per unit mRNA. RNA was purified
using RNeasy (Qiagen, Crawley, UK) and contaminating
DNA was removed with TURBO DNase I (Applied Bio-
systems, Warrington, UK). cDNA was synthesized from
oligo-dT primed RNA using Superscript II (Invitrogen,
Paisley, UK). Real-time PCR reactions were performed
in triplicate using SYBR Green PCR Master Mix on an
ABI7900HT machine (Applied Biosystems, Warrington,
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UK). GFP mRNA levels were normalized to those of the
reference gene RPLP0 [34] and relative expression calcu-
lated using the ΔΔCt method [35]. For analysis of GFP
protein expression, cells were suspended in media con-
taining 1% serum and fluorescence quantified (mean
fluorescent intensity of 104 events after exclusion of
debris/dead cells on forward activated light scatter/side
scatter) at 525 nm using an LSRII machine (BD Bios-
ciences, Oxford, UK).
Ethical issues, patient material, immunohistochemistry
Ethical permissions were obtained from Northern and
Yorkshire MREC (4/MRE03/89) and Leeds East REC
(05/Q1206/136). Postmenopausal female patients with
operable early breast cancer (T1-3, N0-1, M0) proceed-
ing to primary surgery were recruited, written informed
consent was taken, and patients were treated as pre-
viously described in detail [36]. In brief, core biopsies
were taken at time of presentation with a palpable
breast lump and were processed for diagnostic assess-
ments. Patients were given 11-14 days of everolimus
5 mg once daily immediately before tumour resection.
Excision specimens were processed by the pathology
laboratory for diagnostic tests. Clinical/pathological
details of patients are listed elsewhere [36]. Matched
biopsy and excisional tumour blocks from 22 patients
were used. Immunohistochemistry was performed for
Ki67 (mouse monoclonal clone MIB-1; Dako, Glostrup,
Denmark), 4E-BP2 (rabbit polyclonal #2845, Cell Signal-
ling Technology, Beverly, USA), eIF4E, 4E-BP1 and
phosphoThr37/46 4E-BP1 (as for Westerns) exactly as
described and validated previously [31,36] on single sec-
tions from each case for each antigen. Ki67 was quanti-
fied using a previously validated protocol for scoring
percentages of stained cells as proportions of total can-
cer cells [37], and these data have been published [36].
Other markers were scored by two independent indivi-
duals (VJC, CS) taking into account average intensity
and percentage of positively stained tumour cells. Inten-
sity scores (0 no staining, 1 weak, 2 moderate and 3
strong) were added to percentages scores (1 <5%, 2 6-
25%, 3 26-75% and 4 >75%) giving totals of 0 or 2-7.
Consensus scores were determined for sections with dif-
ferent initial scores; scoring was overseen by a consul-
tant breast histopathologist (AMH).
Statistics
Analyses were performed using Student’s T Test, Spear-
man’s rho correlation, or linear regression in Excel v12
(Microsoft, Redmond, USA), SPSS v15 (SPSS, Chicago,
USA) and MATLAB (MathWorks, Natick, USA). Tests
were two sided; p < 0.05 was considered to indicate
significance.
Results
Cell lines show a range of sensitivities to rapamycin
Rapamycin and its derivatives induce a broad range of
responses when used as cancer therapeutics with growth
of some cancers reduced while others are resistant. We
were interested to examine this variation, therefore we
treated a panel of cell lines with rapamycin and deter-
mined drug sensitivities. The panel was representative of
the three most common cancers in the UK: colorectal
(SW480 and Caco2, moderately-differentiated and het-
erogeneous colon cancer lines respectively); lung
(U2020, small cell, and H1299 and A549, non small cell
cancer lines); and breast (MCF7 and MDA-MB-231,
luminal and basal breast cancer lines respectively). In
addition, two immortal breast epithelial lines of non-
cancer origin (HB2 and MCF10A) were examined in
order to allow study of potential differential sensitivity
between cancer and non-cancer cells. We treated cells
with doses of rapamycin and determined proliferation/
survival relative to control treated cells using MTT
assays after 48 h (Figure 1A). Sensitivities to the highest
dose are shown in Figure 1B. As expected a range of
sensitivities were seen, with a three fold difference
between the most sensitive (MCF7) and most resistant
(MDA-MB-231). Cells of non-cancer origin (HB2 and
MCF10A) were found to have sensitivities between
these extremes.
The phosphorylation state of 4E-BP1 does not predict
rapamycin sensitivity
Next, we aimed to identify molecular markers that cor-
related with these sensitivities, therefore that might
represent predictive biomarkers for mTOR inhibitors.
Potential biomarkers have previously been proposed; of
particular interest was the phosphorylation status of 4E-
BP1 [24] since the 4E-BP1/eIF4E axis has been shown
to be critical for mTOR-mediated transformation [38].
4E-BP1 is directly phosphorylated by mTORC1 [12],
potentially leading to increased eIF4E activity and
enhanced translation of cancer-related transcripts
[15-17]. Thus, levels of phosphorylated 4E-BP1 may
reflect contributions of mTORC1-signalling to cancer-
associated translational deregulation, and consequently
the sensitivity of such deregulated cells to mTOR inhibi-
tion. We performed Western blot analysis of levels of
mTORC1-dependent 4E-BP1 phosphorylation (Thr37/
Thr46) in the same cell lines as before (Figure 2A). At
least three different phosphorylated 4E-BP1 (phospho-
4E-BP1) species were seen, representing various combi-
nations of the seven potential phosphorylation events
[39-41]. We found no correlation between phospho-4E-
BP1 and rapamycin sensitivity (compare Figures 2A
and 1B). However, levels of phospho-4E-BP1 reflect not
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only mTORC1 activity but also levels of overall 4E-BP1,
therefore we also analysed total 4E-BP1 expression (Fig-
ure 2B) and determined the ratios of phospho- to total
4E-BP1 (Figure 2C) as a measure of mTORC1’s influ-
ence on 4E-BP1 function, as previously reported [25].
We found no correlation between this measure and
rapamycin sensitivity. Finally, 4E-BP1’s influence on cel-
lular behaviour is determined by the amount of eIF4E
remaining unbound by 4E-BP1, consequently, variation
in eIF4E expression would also have a critical role. We
analysed eIF4E expression and found greater than three
fold variation in eIF4E expression (Figure 2D). We con-
cluded that levels of phospho-4E-BP1 do not correlate
with functional influences of mTORC1 on cap-
dependent translation, partly as substantial variations in
total 4E-BP1 and eIF4E expression mask this direct rela-
tionship. A measure of eIF4E activity would, however,
take into account the variation in expression of all these
components and might provide a better predictive
marker.
Assessment of translational efficiencies defined by a
structured 5’UTR; estimation of eIF4E activity
Our hypothesis was that assessment of the activity of a
key mTORC1 regulated pathway gives direct insights
into the contribution of deregulated mTORC1 to cellu-
lar behaviour and therefore, potentially, into likely sensi-
tivity to mTOR-inhibitors. A critical effect of up-
regulated mTORC1 is to up-regulate eIF4E activity
thereby enhancing translational efficiencies of transcripts
with structured 5’UTRs [15]; therefore, we designed an
assay to measure these translational efficiencies. We
have previously shown that a 5’UTR from human axin2
transcripts contains a sixty nucleotide sequence that is
predicted to form a stable stem-loop structure [29]. This
sequences meets the criteria associated with UTRs that
determine differential translational efficiencies in
response to changes in eIF4E activity [16], while lacking
other translation regulatory motifs (e.g. upstream AUG
codons or binding sites for trans-acting proteins). In
addition, we previously demonstrated that this sequence
Figure 1 Sensitivities of cell lines to rapamycin vary by up to three fold. A) Cells were treated with either control, or different doses of
rapamycin and growth/proliferation was monitored using MTT assays. MTT readings after 48 hours are shown relative to control. B) Relative
sensitivities to rapamycin are shown; these are the % reductions in growth/proliferation caused by 100 nM rapamycin. Data points represent
means (+/- standard deviations) from five independent wells of cells within a representative experiment. Data from independent repeat
experiments are presented in Additional file 2, Figure S1 to demonstrate the reproducibility of these measurements in each cell line.
Figure 2 Levels of 4E-BP1 phosphorylation do not predict
rapamycin sensitivity. Expression of phospho-4E-BP1 (A), total
4E-BP1 (B) and eIF4E (D) was examined in the cell lines shown by
Western blot. Relative ratios of phospho-4E-BP1 to total 4E-BP1 are
shown in C. Equal masses of total protein were loaded in each lane
as determined by triplicate measurements with colourimetric
protein mass assays, and expression was quantified by densitometry.
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determined cell type specific translational efficiencies
[29]. We now wished to examine whether the transla-
tional efficiency defined by this sequence would respond
to changes in eIF4E activity, and could therefore be
representative of mTORC1’s influence on cap-dependent
translation of structured transcripts. The sequence was
cloned upstream of the GFP reading frame in an expres-
sion vector. MCF7 cells were transiently transfected with
an equal copy number of vectors to allow expression of
GFP mRNAs with either a control non-regulatory
5’UTR or this sequence as a 5’UTR, along with either
empty expression plasmids or plasmids allowing eIF4E
over-expression. GFP protein expression was measured
by flow-cytometry and GFP mRNA expression was mea-
sured by qPCR allowing determination of relative trans-
lational efficiencies for each GFP message as previously
described [32,33] (Figure 3A). Western blot analyses
were used to confirm expression of exogenous eIF4E
and GFP (Figure 3B). The translational efficiency of the
control reporter was not significantly altered by eIF4E
over-expression (compare lanes 1 and 2), demonstrating
that eIF4E over-expression did not cause a general
enhancement of translation. As previously reported [29],
the structured 5’UTR conferred repression of translation
(compare lanes 1 and 3; p = 0.002). Critically, this
repression was overcome by exogenous eIF4E (compare
lanes 3 and 4; p = 0.002), resulting in translation with
the same efficiency as messages lacking inhibitory
5’UTRs. We concluded that this reporter did indeed
respond to changes in eIF4E activity and thus can be
used to provide an estimate of eIF4E-dependent transla-
tion from structured 5’UTRs.
Estimates of eIF4E activity predict rapamycin sensitivity in
tissue culture cells
Relative translational efficiencies specified by this eIF4E-
responsive 5’UTR were determined in the panel of cell
lines. Cells were transiently transfected with vectors to
allow expression of GFP mRNAs with control or the
structured 5’UTR as before, and translational efficiencies
were determined (Figure 4A). A range of translational
efficiencies was seen, with A549 cells determining the
lowest, and HB2 cells the highest (Figure 4B). Surpris-
ingly, the two cells lines of non-cancer origin (HB2 and
MCF10A) were found to determine relatively efficient
translation from the reporter 5’UTR. Importantly, trans-
lational efficiencies specified by the eIF4E-responsive
5’UTR correlated with rapamycin sensitivity (Figure 5).
Initially, we analysed this relationship using Spearman’s
rank correlation coefficient; we found a strong and
significant positive association (r = 0.72; p = 0.037).
Figure 3 Translational efficiency specified by a structured
5’UTR reporter responds to changes in eIF4E activity.
A) Reporters were constructed to express mRNAs containing the
GFP reading frame preceded by a control 5’UTR lacking regulatory
motifs (control) or a sequence predicted to form a stable stem-loop
structure (structured). MCF7 cells were transiently transfected with
equal copy numbers of either control or structured reporters along
with either empty expression vector (-) or vector to allow over-
expression of eIF4E (+). GFP protein and mRNA were quantified by
flow-cytometry and real-time PCR respectively. Translational
efficiency (protein synthesised per unit mRNA) is presented relative
to the control. Data points represent means (+/-standard deviations)
of values from three separate wells of cells within a representative
experiment. B) Expression of exogenous proteins was confirmed
within cells transfected with control GFP reporter and vector to
allow over-expression of eIF4E as shown by Western blot analysis
for the HA-epitope tag; exogenous GFP and eIF4E both include this
epitope. Note that the small reduction in GFP protein associated
with eIF4E-transfection does not result from a change in
translational efficiency (see Panel A).
Satheesha et al. Molecular Cancer 2011, 10:19
http://www.molecular-cancer.com/content/10/1/19
Page 5 of 10
However, the correlation was particularly evident in 8/9
cell lines; if MCF7 cells, which were more sensitive to
rapamycin than predicted, were excluded the strength
and significance of the relationship was increased (r =
0.83; p = 0.015). Similarly in linear regression, a highly
significant relationship was seen when MCF7 cells were
excluded from the analysis (Figure 5; p = 0.0037).
Estimated eIF4E activity in breast tumours does not
predict reduced tumour proliferation after preoperative
treatment with the rapamycin derivative everolimus
Next, we wished to examine whether eIF4E activities
within tumour cells predict clinical responses to mTOR
inhibition in cancer patients, and whether changes in
eIF4E activities after treatment reflect these responses.
Everolimus is a rapamycin-derivative with improved oral
bioavailability that is currently undergoing trials as a
cancer therapeutic. We recently performed a clinical
trial examining effects of everolimus on tumour cell
proliferation when given preoperatively as a single agent
to breast cancer patients [36]. By examining Ki67 stain-
ing in matched pre-treatment biopsy and post-treatment
excisional samples, we found that 5 mg everolimus daily
for up to 14 days was significantly associated with
reduced tumour cell proliferation. Unfortunately, it is
not possible to estimate eIF4E activities directly in
tumour samples such as these using the reporters
Figure 4 eIF4E activities vary in different cell lines. A) Cells were transiently transfected with equal copy numbers of plasmids to allow
expression of transcripts with the GFP reading frame preceded by either a control 5’UTR lacking regulatory motifs (con) or the eIF4E-responsive
structured 5’UTR (struc). GFP protein and mRNA were quantified by flow-cytometry and real-time PCR respectively. Translational efficiency
(protein synthesised per unit mRNA) is presented relative to the control. Data points represent means (+/-standard deviations) of values from
three separate wells of cells from two independent experiments (a total of six values). B) Translational efficiencies of transcripts with eIF4E-
responsive 5’UTRs in the 9 cells lines.
Figure 5 Experimentally determined eIF4E activities correlate
with sensitivities to rapamycin. Data from Figures 4B and 1B
were plotted for each cell line as labelled. Linear regression was
performed to determine the relationship in the cell lines excluding
the outlier, MCF7 cells; the linear model is shown as a line (black)
with 95% confidence intervals (grey lines) (p = 0.0037).
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described above. As an alternative we estimated eIF4E
activity from expression and phosphorylation states of
multiple regulators of the translational initiation path-
way (Figure 6; Table 1). We have previously described
the development and prognostic value of this estimate
in breast tumours [31]. Expression levels of eIF4E, 4E-
BP1, 4E-BP2 and Thr37/Thr46 phosphorylated 4E-BP1
(phospho-4E-BP1) within tumour cells were determined
semi-quantitatively in matched pre- and post-treatment
tumour samples from 22 patients using immunohisto-
chemistry. Activity of eIF4E was estimated by combining
these scores to reflect the inhibitory influence of 4E-BPs
on eIF4E, and the activating influence of 4E-BP1 phos-
phorylation on eIF4E, using a formula previously derived
from regression modelling of individual contributions of
each component to prognosis in a large cohort of breast
cancer patients: X-B1/4+PB1/2-B2/4, where X, B1, PB1
and B2 represent scores for eIF4E, 4E-BP1 phospho-4E-
BP1 and 4E-BP2 respectively [31]. We previously
showed that this measure gave improved insights into
the prognostic influence of eIF4E by reflecting eIF4E
activity more accurately than examining eIF4E expres-
sion levels alone.
17/22 tumours showed reduced Ki67 scores after
treatment (mean reduction 48%) indicating apparent
responses to everolimus (Table 1). Disappointingly, esti-
mates of pre-treatment eIF4E activity did not predict
the occurrence or extent of these responses. Similarly,
pre-treatment phospho-4E-BP1 levels had no predictive
value. Estimated eIF4E activity was, however, reduced in
post-treatment samples (mean change in score -1.7;
range -8 to +1.25; p < 0.001) but surprisingly this was
not attributable to reduced phospho-4E-BP1. Phospho-
4E-BP1 expression was reduced after treatment (mean
-2.3; range -6 to +1; p < 0.001), suggesting a reduction
in mTOR-dependent phosphorylation of 4E-BP1, but
this reduction in phospho-4E-BP1 was not significantly
correlated with the reduction in estimated eIF4E activity,
and changes in levels of the other components had
strong influences on estimated eIF4E activity. For exam-
ple, 4E-BP1 expression changed considerably (mean
-0.3; range -5 to +5; p = 0.01), meaning that 8 individual
decreases in phospho-4E-BP1 could be explained at least
partially by reductions in total 4E-BP1, as opposed to
reduced phosphorylation. This explanation is supported
by observations that the phospho-4E-BP1 species exam-
ined here (Thr37/46) can be relatively resistant to
mTOR inhibition [39]. 4E-BP2 expression also fre-
quently changed (mean +2.2; range -2 to +7; p < 0.001),
while some individuals showed dramatic changes in
expression of eIF4E (mean -0.1; range -6 to +4). Inter-
estingly changes in eIF4E and 4E-BP1 were positively
associated (r = 0.60, p = 0.003), often resulting in rela-
tively small changes in estimated eIF4E activity, despite
substantial fluctuations in expression of the individual
proteins. Critically, neither reduced estimated eIF4E
activity or reduced phospho-4E-BP1 correlated with
reduced Ki67.
High estimated eIF4E activities in breast tumours are
associated with everolimus-induced changes in eIF4E
regulation
A striking observation was that post-treatment levels of
eIF4E and the 4E-BPs frequently varied considerably
from pre-treatment levels. Our hypothesis was that
these changes represent development of acquired resis-
tance to inhibition of eIF4E activity, by induction of
changes in eIF4E regulation within tumour cells or by
clonal selection of cells with different eIF4E-related
expression profiles. Importantly, this proposed
acquired resistance is not necessarily reflected in
higher proliferation rates. Using this hypothesis, one
would predict that tumours with high pre-treatment
estimated eIF4E activities would be most subject to
drug-induced expression changes or to clonal selection
pressures, and would show the greatest adaptive
changes in eIF4E regulation. In fact, high estimated
eIF4E activity pre-treatment did positively correlate
with the combined magnitude of changes in expression
Figure 6 Representative tumour sections showing
immunoreactivity as labelled. Staining within these sections was
scored as eIF4E 6, 4E-BP1 6, 4E-BP2 6 and phospho-4E-BP1 5. Scale
bar represents 0.05 mm.
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of the four markers (r = 0.46, p = 0.03) and, in parti-
cular, with increases in 4E-BP2 expression (r = 0.55,
p < 0.01). We concluded that high estimated eIF4E
activity may, in fact, predict tumour response to evero-
limus; however this response is not the expected
reduction in proliferation, but is development of
changes in eIF4E regulation, presumably to promote
everolimus resistance.
Discussion
The mTOR pathway, which promotes cell proliferation,
presents an attractive target for cancer therapy since it
is deregulated in a wide range of cancer types and a
large proportion of cases of each type [2]. However,
resistance of some cancers to mTOR-directed therapeu-
tics has limited the success of mTOR inhibitors. We
have examined this variation in response, initially, in cell
lines. As expected, and in accordance with other pub-
lished work [42-44], we found a range of sensitivities to
rapamycin (Figure 1). Surprisingly, we found that cancer
cell lines were not more sensitive than cells of non-
cancer origin, despite the well established preferential
sensitivity of cancer cells over non-cancer cells in animal
models and, to an extent, in humans [3-5]. This obser-
vation most likely demonstrates that up-regulation of
mTORC1, and consequently sensitivity to its inhibition,
is actually associated with growth as opposed to malig-
nancy, and therefore that highly-proliferative, immortal,
non-cancer cell lines are un-representative of ‘normal’,
relatively slowly growing, epithelial cells with respect to
mTORC1 signalling. The efficacy of rapamycin as an
immunosuppressant drug [1] and the side-effects seen
in cancer therapies [21,22] support the view that prolif-
erating cells are targeted.
Identification of predictive biomarkers for mTOR-
targeted therapies such as rapamycin or everolimus has
become a research focus [2]. Levels of phosphorylated
mTOR, S6K1 or 4E-BP1 have been seen as logical mar-
kers as these phosphorylation events induce mTOR
activity or are directly catalysed by mTORC1, and there-
fore levels may reflect the extent of mTORC1 deregula-
tion. However, in principle, it is obvious that levels of
these species may not correlate directly with their influ-
ences on down-stream signalling and consequent
changes in cellular behaviour, since these influences
would also be defined by expression/activity of the other
regulatory molecules of the pathways. Despite this, some
predictive value has been demonstrated for each marker
[23,24,27]. We found levels of phosphorylated 4E-BP1,
and the proportions of phospho-4E-BP1 within the total
Table 1 Expression scores for eIF4E (4E), 4E-BP1 (BP1), 4E-BP2 (BP2), phospho-4E-BP1 (pBP1) and Ki67, and estimates
of eIF4E activity in matched pre- and post-treatment samples from patients treated with 11-14 days of everolimus
pre-treatment post-treatment
Patient 4E BP1 BP2 pBP1 activity Ki67 4E BP1 BP2 pBP1 activity Ki67
1 6 5 5 6 6.5 15.5 0 0 6 0 -1.5 23.1
2 3 5 5 5 3 6.0 0 3 5 0 -2 0.9
3 3 3 5 4 3 7.6 5 4 5 3 4.25 2.7
4 5 6 6 6 5 22.1 6 7 7 6 5.5 16.7
5 4 6 4 6 4.5 44.6 4 4 4 3 3.5 29.7
6 4 0 6 6 5.5 34.2 5 5 5 4 4.5 23.0
7 3 6 5 5 1.75 4.2 4 4 4 0 2 2.7
8 4 3 4 2 3.25 1.6 3 0 4 3 3.5 4.4
9 5 7 7 6 4.5 15.3 5 6 7 5 4.25 6.8
10 5 7 6 5 4.25 22.6 5 3 6 2 3.75 6.5
11 5 0 6 2 4.5 18.4 5 0 4 0 4 7.4
12 5 3 6 6 5.75 3.6 6 6 7 3 4.25 47.2
13 4 4 0 5 5.5 10.1 6 5 5 2 4.5 3.6
14 6 4 0 6 8 17.4 4 4 6 2 2.5 10.1
15 5 0 0 6 8 10.2 4 0 7 5 4.75 17.8
16 5 4 0 4 6 10.6 6 4 6 2 4.5 13.0
17 4 4 2 6 5.5 16.2 6 3 5 4 6 8.4
18 0 0 0 4 2 6.2 4 2 7 0 1.75 5.2
19 4 4 0 5 5.5 18.2 7 7 5 3 5.5 9.0
20 6 4 0 7 8.5 18.0 5 6 7 5 4.25 3.8
21 5 4 6 6 5.5 20.0 0 0 5 5 1.25 13.4
22 5 4 2 4 5.5 6.8 4 4 7 3 2.75 5.3
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pool of 4E-BP1 to be unrelated to rapamycin sensitivity
in tissue culture, in accordance with previous work in a
cell line panel also containing MCF7 and MDA-MB-231
cells [42]. Moreover, we showed that this, in fact, was
the expected result in the context of variation in 4E-BP1
and eIF4E expression (Figure 2). As an alternative pre-
dictive marker, we developed assays to estimate one of
the key functional end-points of mTORC1 signalling,
eIF4E activity. We found this estimate to be significantly
associated with rapamycin sensitivity in cell culture. It
was notable, however, that estimated eIF4E activity was
the most significant predictor of rapamycin sensitivity
for 8 of the cell lines (Figure 5), while MCF7 cells were
twice as sensitive as predicted by this relationship.
MCF7 cells over-express S6K1, on account of amplifica-
tion of its gene [45]; one explanation for enhanced sen-
sitivity in MCF7 cells may be that with constitutively
high S6K1 activity, the cells are dependent upon
mTOR-induced S6K functions such as more general
translational effects [46]. In support of this, S6K1 over-
expression has previously been associated with increased
rapamycin sensitivity [42].
Importantly, we also examined whether estimates of
pre-treatment eIF4E activity in clinical breast tumours
predicted response to the mTOR inhibitor everolimus.
Disappointingly and in contrast to our in vitro work, we
found estimated eIF4E activity did not predict response
to mTOR inhibition as assessed by change in tumour
cell proliferation. However, we did find that pre-
treatment eIF4E activity in tumours was significantly
associated with substantial changes in the expression of
eIF4E and its regulators post-treatment. We interpret
this to suggest that cancers with high eIF4E activity may
indeed have been sensitive to everolimus, as suggested
by our in vitro data, but that the cells remaining after
two weeks of drug treatment reflect selection to acquire
drug resistance by changing the pathways regulating
eIF4E function. Data show that this proposed resistance
is not necessarily associated with lower estimated eIF4E
activity or higher proliferative rates. This hypothesis
highlights a difference between short-term (two day)
sensitivity assays in vitro and longer term (two week)
drug treatments in patients; in the latter case it is inevi-
tably more difficult to assess the early response of
tumour cells to treatment and there is considerable
scope for acquired changes to take place. Finally, it is
interesting to note that our data do not support the use
of phospho-4E-BP1 as either a predictive or pharmaco-
dynamic marker for mTOR inhibitors as some have
attempted [2,21] since it is clear that changes in phos-
pho-4E-BP1 relate not only to inhibition of 4E-BP1
phosphorylation, but also to dramatic changes in overall
4E-BP1 expression.
Additional material
Additional file 1: Table S1. Cell culture and transfection conditions.
Additional file 2: Figure S1. Sensitivities of cell lines to rapamycin are
reproducible. Relative sensitivities to 100 nM rapamycin are shown; these
are the % reductions in growth/proliferation caused by the drug as
compared to control treated cells. Data from Figure 1B are reproduced
(filled bars) alongside independent repeat analyses (open bars). Data
points represent means (+/- standard deviations) from five independent
wells of cells.
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